Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zirconium-89 patritumab deruxtecan
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zirconium-89 patritumab deruxtecan is a radiolabeled antibody-drug conjugate (ADC) designed for positron emission tomography (PET) imaging. It consists of the HER3-targeting ADC patritumab deruxtecan (HER3-DXd) labeled with the positron-emitting radioisotope zirconium-89 (89Zr). Patritumab deruxtecan itself comprises a human IgG1 monoclonal antibody (patritumab) linked to a topoisomerase I inhibitor payload (deruxtecan) via a cleavable tetrapeptide-based linker. By utilizing the 89Zr label, this agent allows for the non-invasive quantification and visualization of HER3 expression and drug distribution in vivo. It is primarily being investigated in clinical trials for patients with advanced non-small cell lung cancer (NSCLC), particularly those with EGFR mutations, to optimize dosing and predict treatment response.
- Other names
- radiolabelled patritumab deruxtecanzirconium-89 labeled patritumab deruxtecanzirconium89 labeled patritumab deruxtecanzirconium 89 labeled patritumab deruxtecan
02
Targets
TOP1 (DNA Topoisomerase I)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on zirconium-89 patritumab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zirconium-89 patritumab deruxtecan.